In melanoma clinical practice, clinicians show performance gaps in obtaining appropriate and prompt BRAF testing, optimal incorporation of BRAF/MEK inhibitor therapy, management of brain metastases, promotion of adherence to oral therapy, management of targeted therapy side effects, and provision of interdisciplinary care. BRAF/MEK Inhibitor Therapy for Melanoma: Improving Outcomes Through Interdisciplinary Care is designed to address the educational needs of various members of the care team regarding targeted therapy, illustrating the use of the Melanoma Nursing Initiative materials. The interactive cases in this initiative will challenge the healthcare team to provide state-of-the-art, patient-centric therapy for patients with melanoma, leveraging targeted therapy to optimize outcomes.
Release Date: 5/14/2020
Expiration Date: 5/13/2021
Estimated Time to Complete the Activity: 1 hr
Media: Interactive, text-based activity
Jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and AIM at Melanoma Foundation.
This activity is supported by independent educational grants from Array BioPharma and Novartis Pharmaceuticals.
This activity is intended for oncology care providers (including physicians, nurse practitioners, physician assistants, registered nurses, and other HCPs) who care for patients with melanoma.
Upon completing this activity, the participant should be better able to:
Ryan J. Sullivan, MD
Assistant Professor
Hematology/Oncology
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Krista M. Rubin, RN, MS, FNP-BC
Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine; Terranova Medica, LLC; and AIM at Melanoma Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.7 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
Ryan J. Sullivan, MD
CONSULTING FEES:
Asana, Bristol-Myers Squibb, Merck & Co., Inc., Novartis Pharmaceuticals, and Replimune
CONTRACTED RESEARCH:
Merck & Co., Inc., and Amgen
Krista M. Rubin, RN, MS, FNP-BC
CONSULTING FEES:
Bristol-Myers Squibb, Merck & Co., Inc., and EMD Serono.
The PIM; Terranova Medica, LLC; and AIM at Melanoma Foundation planners and managers have nothing to disclose.
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and PIM are committed to protecting the privacy of those who choose to participate in activities on aimatcancerce.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and PIM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There is no charge for this activity.
Jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and AIM at Melanoma Foundation.
This activity is supported by independent educational grants from Array BioPharma and Novartis Pharmaceuticals.
For further information, contact Tom Davis by telephone (877-276-4523), fax (805-648-8070), or email (tdavis@terranovamedica.com).
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.
Copyright © 2020 PIM, AIM at Melanoma, and Terranova Medica, LLC.